This prospective, randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group was designed to test the effectiveness and safety of adding the hypoxic cell sensitizer tirapazamine (TPZ) to standard cisplatin (CIS) chemoradiotherapy in locally advanced cervix cancer.
INTRODUCTION
Historically, invasive cervical cancer has been treated with either surgery or radiation therapy. In early-stage disease (ie, International Federation of Obstetrics and Gynecology [FIGO] stage Յ IIA), surgery and radiotherapy are equally efficacious, with differing toxicity profiles. In locally advancedstage disease (ie, FIGO stage IIB to IVA), the role of surgery is limited, and curative therapy remains chemoradiotherapy using cisplatin (CIS). 1 In 2012, approximately 12,170 patient cases of invasive cervical cancer were diagnosed, and 4,220 women died as a result of this disease in the United States, with advanced-stage disease accounting for both the majority of patient cases diagnosed and the associated deaths. Despite improvements in progression-free survival (PFS) with chemoradiotherapy, there is still a significant risk of both local recurrence and distant relapse in patients with locally advanced cervix cancer. 2 Current investigations and previously published studies by large multi-institutional groups have examined the role of chemotherapy as a radiation sensitizer in the treatment of locally advanced cervical cancer. On the basis of the positive results of these five trials, the National Cancer Institute (NCI) released a clinical announcement in 1999
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supporting the use of chemoradiotherapy as the standard of care in the treatment of patients with locally advanced cervical cancer. [3] [4] [5] [6] [7] Additional trials have not demonstrated regimens more efficacious than irradiation and CIS. The Gynecologic Oncology Group (GOG) compared the efficacy of fluorouracil (FU) versus CIS as radiation sensitizers. 8 This trial closed when a planned interim futility analysis demonstrated adding protracted venous FU infusion to irradiation was unlikely to provide a PFS benefit when compared with standard CIS chemoradiotherapy. Another GOG trial evaluated the addition of erythropoietin to CIS chemoradiotherapy to maintain a minimal hemoglobin level Ͼ 12.0 g/dL versus chemoradiotherapy with standard hemoglobin support to maintain a hemoglobin level Ͼ 10.0 g/dL.
9 Unfortunately, this attempt to optimize oxygen delivery was associated with toxicity, leading to early study closure with no evaluable survival outcome.
Tirapazamine (TPZ) is a bioreductively activated, hypoxiaselective antitumor agent of the benzotriazine series, which is 35ϫ to 450ϫ more cytotoxic (dependent on tumor cell line studied) to hypoxic cells than well-oxygenated cells. 10 It is bioactivated to a cytotoxic metabolite by electron transfer. 11, 12 This one-electron reduction product, an oxidizing radical anion, causes extensive single-and double-strand breaks in DNA. It may also accentuate DNA damage induced by irradiation or DNA-damaging cytotoxic agents by inhibiting DNA repair. 13 Use of TPZ in a chemoradiotherapy regimen for cervical cancer makes biologic sense, because tumor hypoxia occurs in solid tumors and seems to be a contributing factor to irradiation resistance and treatment failure.
14 Of further importance is the finding from preclinical studies that TPZ is synergistic with CIS by markedly increasing CIS cytotoxicity.
15
This may be the primary cause of antitumor efficacy, because in a number of models, the level of cytotoxicity of TPZ alone is quite low, whereas the combination of TPZ and CIS increases the level of cell kill by many orders of magnitude. 16, 17 In the 5 years preceding this trial, TPZ had been used experimentally with CIS with or without radiation therapy in other solid tumors. 18, 19 Given the evidence suggesting patients with cervical cancer are adversely affected by hypoxic conditions, it was reasonable to evaluate TPZ in an attempt to improve outcomes in this group of patients. Early clinical studies in head and neck and non-small-cell lung cancers support the preclinical findings of TPZ/CIS synergism. 20 Toxicity was mainly limited to fatigue and muscle cramps in patients with lung cancer. Hematologic toxicity was seen in those with head and neck cancer, related to dose and schedule. 20, 21 Clinical development of TPZ in cervix cancer was most promising when administered in combination with CIS in patients with recurrent cervical cancer. In a phase II trial by Malof et al, 22 36 patients were treated with TPZ/CIS, with an overall response rate (partial and complete responses) of 27.8%. In a separate phase II trial conducted by the Southwest Oncology Group, 53 patients were treated with TPZ/ CIS, yielding an overall response rate of 32.1%.
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The only experience in patients with cervical cancer undergoing chemoradiotherapy before the initiation of this study was limited to 15 patients in a phase I/II trial. These patients presented with locally advanced cervical cancer and were treated with TPZ once per week, CIS once every other week, and radiation therapy once per day. 24 The maximum-tolerated dose chosen from this study was TPZ 290 mg/m 2 and CIS 75 mg/m 2 on days 1, 15, and 29 and TPZ 220 mg/m 2 on days 8, 10, 12, 22, 24, and 26 concurrent with radiation therapy. Of the 15 patients treated in this trial, pelvic control was achieved in 12 (80%) of 15, with a minimum follow-up of 3 years. On the basis of the potential clinical advantages of the addition of TPZ to CIS and with a known maximum-tolerated dose for this regimen, GOG initiated the current study, a phase III randomized trial of weekly CIS and irradiation versus CIS and TPZ (IND #46525) and irradiation in patients with stage IB2 or IIA (tumor size Ͼ 4 cm) or IIB, IIIB, or IVA cervical carcinoma limited to the pelvis.
PATIENTS AND METHODS
GOG Protocol 219 was a prospective, randomized phase III trial comparing the addition of TPZ to standard CIS-based chemoradiotherapy in patients with locally advanced cervical cancer. Patients with primary, untreated, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervixclinical stage IB2 or IIA (tumor size Ͼ 4 cm) or IIB, IIIB, or IVA-were eligible for participation. Staging was defined by FIGO guidelines and based on clinical criteria. Surgical staging was not permitted, although lymph node status at the time of surgery (if performed) could be used for eligibility criteria purposes. Although computed tomography scans were required for eligibility purposes, they were not part of the staging criteria. Eligibility was confirmed through central review by the GOG Pathology Committee. Eligibility criteria also included the following: no evidence of para-aortic lymph node or distant metastasis on pretreatment imaging; adequate bone marrow, renal, and hepatic function; GOG performance status Յ 3; no concurrent malignancy or prior malignancy within 5 years, excluding nonmelanoma skin cancer; signed informed consent; and approval by the institutional review board at each participating institution.
Study Design
The primary end point of the study was to determine if combining TPZ with CIS during radiation therapy increases PFS when compared with weekly CIS and radiation therapy in this patient population. Secondary end points included the impact on overall survival (OS) and assessment of treatment-related toxicity. Patients were stratified based on stage at diagnosis, cooperative group from which they were enrolled, type of brachytherapy (low-dose [LDR] v high-dose radiation [HDR]), and whether para-aortic lymph nodes were assess surgically (yes v no). 
Statistical Methods
Random assignment with equal probability of assignment to each treatment regimen was carried out by dynamic allocation, balancing treatment assignment within cooperative group (GOG, National Cancer Institute of Canada Clinical Trials Group, or other), FIGO stage (IB2, IIA, IIB, IIIB, or IVA), type of brachytherapy (LDR or HDR), and para-aortic lymph nodes sampled (yes or no). The accrual goal was set at 750 eligible patients, with follow-up until 256 events (146 in control arm). 25 This sample size would provide a statistical power of at least 85% to detect a 30% decrease in the progression hazards rate when testing at a significance level of .05 (one-sided test).
The design included an interim safety analysis after the first 60 patients. If toxicity of grade Ն 3 was seen in a significant number of these patients (predetermined rule had been defined a priori), it was proposed that dose modifications should be recommended. An analogous second safety analysis was planned to further evaluate resolution of any safety concern. In addition, interim efficacy and futility analysis was to occur at 50% of the information time (ie, after observing at least 128 events). Stopping rules assumed two sequential tests were made using O'Brien Fleming spending functions (to determine test boundaries) and that the hazards were proportional.
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PFS was calculated as time in months from study enrollment to disease progression or death for noncensored observations (events) or to date of last contact for censored observations. OS was calculated as time in months from date of study enrollment to death for noncensored observations (events) or to date of last contact for censored observations (ie, patients alive, regardless of disease status). Recurrence site was classified as local if within the pelvic field, as locoregional if in vagina, para-aortic lymph nodes, or abdomen, and as distant otherwise.
Estimated product limits were computed using the KaplanMeier method.
28 Differences in PFS and OS by treatment were evaluated using the log-rank test according to the intent-to-treat principle of eligible patients. 29, 30 Treatment effect on PFS and OS while adjusting for known prognostic factors and enrollment period (pre-v post-dose modification amendment) was accomplished using Cox regression.
31 Screening for chance imbalances between clinical/pathologic characteristics and treatment assignment was performed using Pearson's 2 test at a significance level of 0.1. 32 The Mann-Whitney U test was used when the characteristic was continuous (eg, age). Fisher's exact test was used to assess differences in incidence of maximum adverse event grade (Common Terminology Criteria for Adverse Events, version 3) by treatment regimen. 
RESULTS
A total of 402 patients were enrolled from February 6, 2006, until study closure on September 9, 2009, because of lack of study drug. Of those, 379 were eligible and evaluable in the intent-to-treat analysis (Fig 1 ) . The most common reasons for ineligibility were wrong stage, cell type, or primary cancer in nine of 23 patients. The demographic and tumor characteristics of the enrolled patients are summarized in Table 1 . Patients were primarily white, non-Hispanic women with a good performance status with either FIGO stage IIB or IIIb squamous cell cancer of the cervix.
Of the 379 evaluable patients, 324 completed study therapy without dose-limiting toxicity or progression. Discontinuation for toxicity or refusal of study therapy was slightly higher in the experimental versus control arm (6.5% v 2.6% and 9.2% v 5.2%, respectively). Completion of all prescribed cycles was higher in the control versus experimental arm (93.8% v 82.2%). The differences in these factors were not statistically significant.
There was no impact of treatment arm on the ability to deliver radiation therapy; a detailed summary of treatment length is shown in Appendix Table A1 (online only). A majority of patients (283 [74.7%] of 379) were able to complete both external irradiation and intracavitary brachytherapy in Յ 52 days.
Detailed toxicities for the planned interim safety analyses are listed in Table 2 . There was a statistically significant increase in grade 3 or 4 leukopenia; GI toxicities manifested mainly as nausea, vomiting, and/or diarrhea; and metabolic abnormalities (renal or hepatic function) in the experimental arm at the first interim safety analysis. On the basis of the difference in toxicities between the control and experimental arms, a planned dose reduction was initiated. Analysis of the toxicities after the dose reduction revealed no additional differences between the two arms. The final toxicity analyses for all patients treated at the initial dose level and for all treated patients are summarized in Table 3 and Appendix Table A2 (online only).
As of November 30, 2011, there were 136 events among 379 eligible and evaluable patients in the study. Median follow-up was 28.3 months (interquartile range, 22.2 to 39.1 months). PFS and OS at 3 years (product time estimate) in the control and experimental arms were 64.4% versus 63.0% (unadjusted hazard ratio [HR], 1.047; 95% CI, 0.748 to 1.466; P ϭ .7869) and 70.6% versus 70.5% (unadjusted HR, 1.042; 95% CI, 0.710 to 1.531; P ϭ .8333), respectively (Figs 2 and  3) . In multivariable analysis adjusting for known prognostics factors (age and stage) and enrollment period (pre-v post-dose modification amendment), the treatment effects on PFS (HR, 1.063; 95% CI, 0.649 to 1.708; P ϭ .8344) and OS (HR, 1.174; 95% CI, 0.652 to 2.112; P ϭ .5929) were insignificant. Furthermore, there was no significant interaction between treatment and enrollment period relative to either PFS (P ϭ .3609) or OS (P ϭ .6158).
Patterns of recurrence in those patients whose disease recurred are summarized in Table 4 . Of note, there was a statistically significant increase in the rate of distant failure at the time of first recurrence in the control arm (Fisher's exact P ϭ .0381). When analyzed by dosing before and after the dose reduction amendment, there was no significant difference noted, although there was a greater trend toward a higher distant failure rate in the control arm before the dose reduction.
DISCUSSION
For women with locally advanced cervical cancer, no regimen has been shown to be superior to CIS chemoradiotherapy. Despite theoretic advantages of adding TPZ to CIS in this patient population, this trial did not demonstrate the superiority of the TPZ/CIS regimen compared with CIS chemoradiotherapy. We conclude that this regimen is tolerable, and in devising an interim safety analysis structurally as part of the statistical design, a dose reduction ameliorated significant toxicity differences between the treatment arms. This type of design was critical given the lack of significant experience with the combination of TPZ and CIS with irradiation in this patient population. It is possible that the inability to complete all designed systemic therapy courses at optimal doses in the experimental arm prevented differences between the arms being demonstrated.
Since the initiation of this study, randomized trials in head and neck cancer have been published evaluating the role of TPZ in addition to standard chemoradiotherapy. A randomized phase II trial designed to assess the efficacy of adding TPZ to FU/CIS chemoradiotherapy in resectable stage IV head and neck cancer demonstrated no improvement in survival for the TPZ arm at the cost of increased hematologic toxicity. 33 A phase III trial of the Trans-Tasman Radiation Oncology Group assessed the addition of TPZ to standard CIS chemoradiotherapy in stages III and IV head and neck cancer. In 861 patients, the addition of TPZ did not demonstrate an improvement in PFS, time to locoregional failure, or Abbreviations: CIS, cisplatin; RT, radiotherapy; TPZ, tirapazamine.
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Renal or hepatic function. quality of life. 34 Our study was not able to meet its planned accrual goal because of a lack of available study drug. The cause of this was multifactorial. However, the lack of a survival advantage and concerns about toxicity in the head and neck cancer population that became known during the course of this study may have been contributing factors working against further development of TPZ. Study accrual was slower than predicted. The complexity of the trial design and associated toxicities may have contributed to the pace of accrual. Given the low overall incidence of locally advanced cervical cancer relative to other cancer types in the United States and Canada and a historically low rate of clinical trial participation among patients with cancer overall, international cooperation may be essential to conduct studies such as this in the future.
Theoretically, treating patients with cancers expressing higher levels of tissue hypoxia with TPZ should be advantageous. This study was not able to demonstrate such an advantage clinically. However, translational science studies using tissue from this study are pending, and whether evidence of hypoxia as a biomarker for TPZ success allows for further development of this agent remains to be seen. In the future, use of hypoxia as a biomarker for treatment success may be beneficial with drugs that function in a fashion similar to that of TPZ.
The observation of a lower distant failure rate in the TPZ arm at initial progression is difficult to explain from a hypothetic perspective, because the potential benefit of TPZ would be in enhancing irradiation efficacy at the primary tumor site. This was not evident in this study. The clinical implications of a lower distant metastatic rate should be improved survival outcomes, again not seen in this study. Further investigation of this finding was negatively affected by the early closure of the trial.
Looking to the future, studies in the treatment of locally advanced cervical cancer may have to move toward questions outside the chemoradiotherapy paradigm because of the limited length of the treatment being studied. Given the evidence for a potential survival benefit with extended therapy beyond chemoradiotherapy seen in both the Peters et al study 7 and a more recent study by Dueñas-González et al, 35 the impact of extended therapy is one area warranting further evaluation. The role of adjuvant chemotherapy after initial chemoradiotherapy is the focus of two large-scale international trials. The Australia New Zealand Gynaecological Oncology Group 0902/ GOG 0274 trial is evaluating the role of adjuvant paclitaxel and carboplatin after chemoradiotherapy in locally advanced disease, and the Radiation Therapy Oncology Group 0724 trial is evaluating the same intervention in early-stage, high-risk disease after radical hysterectomy. Of note, both of these are international, intergroup trials, fulfilling the need for international cooperation.
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